Joint Colloquium on G Protein-Coupled Receptors: Sympoisum III - GPCRs in Pathophysiology and Pathobiology

Tuesday May 11, 2021

1:15 pm - 3:15 pm Eastern Time (ET)


Tremendous scientific advancements over the last decade indicate that GPCR physiology and pharmacology are much more complex than originally thought and that it may be possible to exploit this complexity to treat a wide variety of diseases. The objective of this colloquium is to expose scientists to recent discoveries and multidisciplinary approaches used to study GPCRs and provide opportunities for establishing collaborations that bridge complementary interests.

The two-day event, held May 10-11 in the EB virtual platform, will feature speakers who have made exciting discoveries in GPCR research that range from molecular to systems biology, basic research to translational studies, and pharmacology to biochemistry to physiology.

Thanks to the generosity of our sponsors and support from ASPET, ASBMB, and APS, a ticket for the colloquium is being provided at no extra charge with your paid registration to Experimental Biology.


Jerold Chun - Sanford Burnham Prebys Medical Discovery Institute

Lysophospholipid - LPA and S1P - Receptors in Brain Disorders and Therapeutics

G protein-coupled receptors mediate biological effects of lysophospholipids, including lysophosphatidic acid (LPA), sphingosine 1-phosphate (S1P), and related signaling lipids. A major locus of receptor activity is the brain, and a range of nervous system disorders impacted by LPA or S1P signaling will be reviewed, focusing especially on multiple sclerosis (MS). MS is now being treated by multiple FDA-approved S1P receptor modulators and recent data on receptor mechanisms will be presented.

Kathleen Caron - University of North Carolina - Chapel Hill

Novel Regulatory Functions of GPCRs in Vascular Growth and Remodeling

Willis (Rick) Samson - St. Louis University

Novel Peptide-activated (Orphan) GPCRs: New Insights and Therapeutic Opportunities

Orphan G protein-coupled receptors, proteins for which no known ligand exists, represent an untapped resource for the development of novel therapeutics. We have developed an innovative strategy for the identification of those ligands and the determination of their therapeutic potential. These discoveries promise new approaches to the treatment of a wide variety of conditions including chronic pain, reproductive failure, complications of pregnancy, and diabetes.

Lora Heisler - University of Aberdeen

Targeting GPCRs to Improve Obesity

Last Updated: February 8, 2021
Key Dates
April 27 – 30, 2021

ASPET Annual Meeting at EB 2021

Thank you to our Annual Meeting partners: